Premium
Omeprazole versus famotidine in the short‐term treatment of duodenal ulcer disease
Author(s) -
FAVE G. DELLE,
ANNIBALE B.,
FRANCESCHI M.,
QUATRINI M.,
CASSETTA M. R.,
TORSOLI A.
Publication year - 1992
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1992.tb00560.x
Subject(s) - famotidine , omeprazole , medicine , gastroenterology , duodenal ulcer , endoscopy , randomized controlled trial
SUMMARY The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double‐blind randomized trial comparing 20 mg omeprazole o.m. or 40 mg famotidine nocte with endoscopic examination, symptom recording, laboratory screening and gastrin assay. In a per protocol analysis, the duodenal ulcer healing rates for omeprazole and famotidine, documented by endoscopy, were 62% (68/109) and 33% (39/117) after 2 weeks of treatment ( P < 0.001), 92% (96/104) and 80% (86/108) cumulative after 4 weeks ( P < 0.05), and 99% (102/103) and 92% (96/104) after 6 weeks ( P < 0.05), respectively. The results of this trial demonstrate that 20 mg omeprazole o.m. is superior to 40 mg famotidine nocte in duodenal ulcer healing.